Isolation of cDNA clones of human argininosuccinate lyase and corrected amino acid sequence  by Matuo, Seiji et al.
Volume 234, number 2, 395-399 FEB 06087 July 1988 
Isolation of cDNA clones of human argininosuccinate lyase and 
corrected amino acid sequence 
Seiji Matuo, Michiko Tatsuno, Keiko Kobayashi, Takeyori Saheki, Toshiyuki Miyata”, 
Sadaaki Iwanaga”, Yoshihiro Amaya+ and Masataka Mori+ 
Department of Biochemistry, Faculty of Medicine, Kagoshima University, Kagoshima 890, 
“Department of Biology, Faculty of Science, Kyushu University, Fukuoka 812 and 
+ Institute for Medical Genetics, Kumamoto University Medical School, Kumamoto 862, Japan 
Received 20 May 1988 
In the present study, we isolated clones of human argininosuccinate lyase (ASL) cDNA from a liver cDNA library using 
a clone of rat ASL cDNA and analyzed human ASL cDNA nucleotide sequence. The results reveal that the sequence 
of human ASL cDNA published by O’Brien et al. in 1986 [Proc. Natl. Acad. Sci USA 83,721 l-72151 had one-base dele- 
tions at three independent positions in the coding regions near the COOH-terminus, which caused frame-shift variations 
in the amino acid sequence. Amino acid sequencing of peptides prepared from purified human liver ASL showed our 
predicted amino acid sequence to be correct. 
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1. INTRODUCTION 
Argininosuccinate lyase (ASL) is a urea cycle en- 
zyme which catalyzes the cleavage of argininosuc- 
cinate into arginine and fumarate. Deficiency of 
ASL results in argininosuccinic aciduria, the se- 
cond most frequently found enzyme deficiency in 
the urea cycle [2]. In Japan, more than 10 cases 
have been found and described. We have shown 
that most Japanese patients with argininosuccinic 
aciduria are completely deficient in ASL activity 
and immune cross-reacting material [3,4], but 
Simard et al. [5] reported that, in all of the 28 pa- 
tients in the USA, cross-reacting material was 
detected by Western blotting analysis. 
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The nucleotide sequence presented here has been submitted to 
the EMBL/GenBank database under the accession number 
Yoo753 
In 1986, O’Brien et al. [l] isolated human ASL 
cDNA clones, predicted the amino acid sequence 
and showed partial homology in the deduced 
amino acid sequences between yeast and human 
enzymes. Amaya et al. [6] described the nucleotide 
sequence of rat ASL cDNA clones. They found a 
high homology between the human and the rat en- 
zymes along the entire sequence xcept for the 66 
amino acid residues of the human sequence near 
the COOH-terminus, and suggested that the 
reported amino acid sequence of the corresponding 
region of the human enzyme might arise from the 
different reading frame of the cDNA. We isolated 
cDNA clones for ASL from a human liver cDNA 
library in order to reexamine the human cDNA se- 
quence and to use the cDNA for future analysis of 
ASL deficiency at the molecular level. 
2. MATERIALS AND METHODS 
2.1. Screening of cDNA library and DNA sequence analysis 
Complementary DNA clones for human ASL were isolated 
from a human liver cDNA library constructed in hgtl 1 expres- 
sion vector essentially according to the plaque hybridization 
method of Maniatis et al. [7]. Previously cloned rat ASL cDNA 
[6], labeled with [32P]dCTP, was used as a probe for screening. 
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Fig. 1. Restriction map of human argininosuccinate lyase cDNAs (ASL l-3, ASL l-4 and ASL 2-3) and the strategy for nucleotide 
sequence determination. The scale at the top indicates the nucleotide position relative to the protein initiator codon beginning at 
position 1. The restriction map of human ASL cDNA (AL 3) obtained by O’Brien et al. [l] is also shown. H, SC, Sm, Sa, P, and 
E denote restriction sites cut by restriction enzymes, NindIII, SacI, SmaI, Se/l, PstI and EcoRI, respectively. The protein coding region 
as predicted from the cDNA is indicated by a closed box, and 5’- and 3 ‘-untranslated regions are indicated by open boxes. The arrows 
beneath the cDNAs indicate the direction and extent of sequence determination, starting from the universal primer or reverse primer 
(o), or the specific primer (S,, CTCAGCCCCGACATGCT; SZ, AGTGACAGCTGGTTGAG) (0). 
* -45 -1 
CAG.ACC.CGG.AGh.CCG.MG.CTT.CCG.GAC.GhC.GAG.GM.CCG.CCC.MC. 
. 1 60. 
ATG.GCC.TCC.GAG.AGT.Gffi.AAG.CTT.’K;G.GGT.GGC.CGG.TTT.GTG.GGT.GCA.GTG.GAC.CCC.ATC 
Het-Ala-Ser-Glu-Ser-Gly-Lys-Leu-Trp-Gly-Gl~-Arg-Phe-Val-G~y-Ala-Val-Aap-Pro-Ile ----_---__-_---_---_ 
l 61 Kl I2 120. 
ATG.GAG.MG.TTC.MC.GCG.TCC.ATT.GCC.TAC.GAC.CGG.CAC.CTT.TGG.GAG.GTG.GAT.GTT.CM 
Het-Glu-Ly~-Pha-Arn-Ala-Ser-Ile-Ala-Tyr-Asp-Arg-Hi6-Leu-Trp-Glu-Val-A6p-Va~-Gln --- - 
* 121 KS 160. 
GGC.AGC.~.GCC.TAC.AGC.AGG.GGC.CTG.GAG.MG.GCA.GGG.CTC.CTC.ACC.MG.GCC.GAG.ATG 
Gly-Ser-Lys-Ala-Tyr-Ser-Arg-Gly-Leu-Glu-Lya-Ala-Gly-Leu-Leu-Thr-Lys-Ala-Glu-~et _______ --__---_T__ 
l 181 K4 K5 2401 
GAC.CAG.ATA.CTC.CAT.GGC.CTA.GAC.MG.GTG.GCT.GAG.GAG.TGG.GCC.CAG.GGC.ACC.TTC.AM 
Aep-Gln-Ile-Leu-His-GIy-Leu-Asp-Ly~-Val-Ala-Glu-Glu-Trp-Ala-Gln-Gly-Thr-Phe-Lys 
241 K6 K7 300’ 
~TG.AAC.TCC.MT.GAT.GAG.GA~.ATC.CA,C.ACA.GCC.MT.GAG.CGC.CGC.CTO.MG.GAG.CTC.AT* 
Leu-Asn-Ser-Asn-Asp-Clu-Asp-Ile-Hls-Thr-~Ala-Asn-Glu-Arg-Arg-Lou-Lys-Glu-Leu-Ile 
Fig.2. Nucleotide and deduced amino acid sequences of human argininosuccinate lyase constructed from those of three cDNA clones, 
ASL l-3, ASL l-4 and ASL 2-3. Nucleotides are numbered in the 5’- to 3’-direction, beginning with the first residue of the ATG 
triplet encoding the initiator methionine. Arrowheads above nucleotide sequence at bases 1159, 1170 and 1357 show bases deleted in 
the sequence published by O’Brien et al. [l]. T at base 1164 and A at 1354 are substituted by C and G, respectively, in the sequence 
of O’Brien et al., as indicated. K-peptides predicted to be produced by digestion with lysylendopeptidase are shown by lines beneath 
the amino acid sequence. Dotted lines show that peptides with the amino acid compositions predicted from the nucleotide sequence 
were not isolated by the present HPLC analysis, and solid lines indicate that peptides with the same amino acid compositions were 
isolated. Bold lines with arrows indicate sequenced peptides and the extent of sequencing. After cyanogen-bromide digestion, two 
middle fragments of K-10 were sequenced. 
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. 301 Kl 360. 
GGT.GCA.hCG.GCA.OGG.MG.CTG.CAC.ACO.CCA.CGC(.AGC.CGO.AAT.GAC.CAG.GTQ.GTC.ACA.GAC 
Gly-Ala-Thr-Ala-Gly-Lys-Leu-His-Thr-Gly-~g-Ser-Arg-Asn-Asp-Gln-Val-Va~-Thr-Asp 
361 
KS * 420. 
CTC.AGG.CTG.TGG.ATG.CGG.CAG.ACC.TGC.TCC.ACG.CTC.fCG.GGC.CTC.C~.TGG.GAG.CTC.ATT 
Leu-Arg-Leu-Trp-Het-Arg-Gln-Thr-Cys-Scr-Thr-Leu-Ser-Gly-Leu-Leu-Trp-Glu-Leu-I~e 
. 421 480. 
AGG.ACC.ATG.GTG.GAT.CGG.GCA_GAG.GCG.GM.CGT.GAT.GTT.CTC.TTC.CCG.GGG.TAC.hCC.CAT 
Arg-Thr-Het-Val-Asp-Arg-Ala-Glu-Ala-Gl~~-Arg-Asp-Val-Leu-Phe-Pro-Gly-Tyr-Thr-His . 
* 401 KID 5408 
Tn;.CAG.AGG.GCC.CAG.CCC.ATC.CGC.'K;G.AGC.CAC.TGO.ATT.CTG.AGC.CAC.GCC.GTG.GCh.CTG 
* 541 600* 
AC~.CGA.GAC.TCT.GAG.Cffi.CTG.CTG.GAG.GM.CGO.MG.CGG.ATC.MT.GTC.CTG.CCC.CTG.GGG 
Thr-Arg-Asp-8er-Glu-Arg-Leu-Leu-Glu-Val-~~g-Lys-Arg-Ile-Asn-V~l-Leu-Pro-Leu-Gly _-_-_-__-__ --_--m--w 
* 601 660. 
hGT.GCG.GCC.ATT.GCA.GGC.MT.CCC.C'K;.CG?.GTO.GAC.CGA.GAG.CTG.CTC.CGA.GCA.GM.CTC 
Ser-Gly-Ala-Ile-Ala-Gly-Asn-Pro-Leu-Gly-Val-hsp-Arg-Glu-Leu-Leu-Arg-hla-Glu-Leu ----______________________________ -----------_ 
l 661 720' 
AAC.TTT.GGG.GCC.ATC.ACT.CTC.MC.AGC.A?G.GAT.GCC.ACT.AGT.GAG.CGG.GAC.TTT.GTG.GCC 
~~n-Phe-Gl~-Ala-Ilu-Thr-Leu-Asn-Ser-Hef-Asp-Ala-Thr-Ser-Glu-Arg-Asp-Phe-Val-hla ----_ ----_-_--______________-_______________. 
l 721 III 760. 
GAG.TTC.CTG.TTC.TGG.CGT.TCG.CTG.'PCC.ATG.ACC.CAT.CTC.AGC.A~.ATG.GCC.GAG.GAC.CTC 
~~u~P_h~-~eu-Phe-Tr~--_Arg-Ser-Leu-Cys-Met-Thr-~is-Leu-Ser-Arg-~et-Ala-Glu-Asp-Leu __--- ------___-____-____ __^-----_--___ 
I 781 840. 
ATC.CTC.TAC.n;C.ACC.MG.GM.TTC.AGC.TTC.Gr(i.CAG.CTC.TCA.QAT.GCC.TAC.AGC.ACG.GGA 
Ile-Leu-T~r-Cys-Thr-Lys-Glu-Phe-Ser-Phe-Val-Gln-Leu-Ser-Asp-Ala-Tyr-Ser-Thr-Gly ---__- ___---___ 
l 841 KI2 900. 
AGC.AGC.CTG.An;.CCC.CAG.AAG.C~.MC.CCC.GAC.AGT.TTG.GAG.CTG.ATC.CGG.AGC.AAG.GCT 
Ser-Ser-Leu-Het-Pro-Gln-Lys-Lys-Asn-Pro-Asp-Ser-Leu-Glu-Leu-Ile-Arg-Ser-Lys-Ala - 
* 901 wIltI 960. 
GGG.CGT.GTG.TTT.GGG.CCG.TGT.GCC.GGG.CTC.C'IYi.h'K;.ACC.CTC.MG.GGA.CTT.CCC.AGC.ACC 
Gly-Arg-Val-Phe-Gly-Arg-Cys-hls-Gly-Lcu-Leu-~et-Thr-Leu-Lys-Gly-Leu-Pro-Ser-Thr 
* 961 115 
K16 
1020* 
TAC.MC.hhA.GAC.TTA.CAG.GAG.GAC.MG.GM.GCT.GTC.TTT.GM.G'PG.TCA.GAC.hCT.hTG.AGT 
Tyr-Asn-Lys-hsp-Leu-Gln-Glu-Asp-Lys-Glu-hla-Val-Phe-Glu-Val-Ser-Asp-Thr-~et-Ser --.---_--_--____w -----------_____-_^_____________ 
' 1021 Ill 1080' 
GCC.GTG.CTC.CAG.GTG.GCC.ACT.GGC.GTC.ATC.TCT.ACG.CTG.CAG.ATT.CAC.CM.GAG.MC.hTG 
hla-Val-Leu-Gln-Va1-hla-Thr-Gly-Val-Ile-Ser-Thr-Leu-Gln-Ile-His-Gln-Glu-Asn-~et -------------~~~---__-_~~~-----~--_________________ 
* 1081 II4 1140* 
GGA.CAG.GCT.CTC.AGC.CCC.GAC.ATG.CTO.GCC.ACT.GAC.~TT.GCC.TAT.TAC.CTG.GTC.CGC.AM 
Gly-Gln-Ala-Leu-Ser-Pro-Asp-Met-Leu-Ala-Thr-Asp-Leu-Aln-Tyr-Tyr-I.eu-Val-Arg-Lye ~__-______________--____-_^~-_-~--___-____-____-_-__ 
* 1141 1200. 
GGG.ATG.CCA.TTC.CGC.CAG.GCC.CAT.GAU.GCC.TCC.GGG.~.GCT.GTG.TTC.ATG.GCC.GAG.hCC 
Gly-Het-Pro-Phe-hrg-Gln-Ala-His-Glu-Ala-Ser-Gly-Lyc-Als-Val-Phe-~et-Ala-Glu-Thr ------____----__-_-_ 
' 1201 WI9 w20‘ 1260. 
MG.GGG.GTC.GCC.CTC.MC.CAG.CPC.TCh,.Cn;.CAG.GAG.CTG.ChG.ACC.ATC.AGC.CCC.CTG.TTC 
Lys-Gly-Val-Ala-Leu-Asn-Gln-Leu-Ser-Leu-Gln-Glu-~.eu-Gln-Thr-Ile-Ser-Pro-Leu-Phe ___. 
* 1261 1320. 
TCG.GGC.GAC.GTG.ATC.TGC.GTG.fGG.GAC.TAC.GCC.UC.AGT.C;TG.GAG.CAG.TAT.GGT.GCC.CTG 
* 1321 Ktl. $ v 1380* 
GGC.GGC.ACT.GCG.CGC.TCC.AGC.GTC.GAC.n;G.CM.ATC.CGC.CAG.GTG.CGG.GCG.CTh.CTG.ChG 
G_ly_Gly-Thr-Ala-Arg-Ser-Ser-Val-Asp-Trp-Gln-I~e-Arg-Gln-Va~-Arg-Ala-Leu-Leu-Gln 
* 1381 
GCA.CAG.CAG.GCd.TAG.GTC.CTC.CCA. 
Ala-Gln-Gln-Ala-'** 
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All nucleotide sequencing was performed by the chain- 
termination method of Sanger [8], using an Ml3 sequencing kit. 
M4 and RV primers from Takara or synthetic 17-mer 
oligonucleotides were used as primers. Fuji Censor gels were 
used for electrophoresis. 
2.2. Purification of human liver ASL 
Human liver ASL was purified according to the method of 
Palekar and Mantagos [9] as modified by Tatsuno et al. [4]. The 
purified enzyme had a specific activity of 20 pmol/min per mg 
of protein at 37°C. 
2.3. Sequence analysis of peptides 
The dialyzed enzyme preparation was reduced and treated 
with vinylpyridine. After lyophilization, the Spyridylethylated 
enzyme (400 pg) was digested with lysyl-endopeptidase (2 pg) 
(Wako Pure Chemical Industries, Ltd, Tokyo) in 50 mM Tris- 
HCl, pH 9.0, containing 4 M urea for 8 h at 37°C. The peptides 
obtained were then separated with high-performance liquid 
chromatography (HPLC) on a Vydac protein C4 column (0.46 
x 15 cm). Amino acid composition of the separated peptides 
was determined by the phenylthiocarbamyl method [lo] using a 
Waters Pica-Tag amino acid analysis system after hydrolysis 
for 20 h in an evacuated, sealed tube at 110°C in 5.7 M HCI. 
Automated sequence analyses of the peptides were performed 
on an Applied Biosystems model 477 protein sequencer [l I] 
equipped with a model 120A PTH analyzer. 
3. RESULTS AND DISCUSSION 
From 150000 plaques, 10 positive clones were 
separated using a rat ASL cDNA probe. The 
length of the cDNA inserts cut from the vector 
DNA by EcoRI digestion was 550 to 1100 bp. 
Fig.1 shows the restriction map of the inserts. 
These inserts were further digested by restriction 
enzymes shown in fig. 1, subcloned into pUC18 
and sequenced as indicated. Fig.2 shows the 
nucleotide sequence of human ASL worked out 
from the sequences of three clones, ASL l-3, ASL 
1-4 and ASL 2-3. There was no difference in the 
human ASL cDNA nucleotide sequence between 
our data and O’Brien’s data from postulated in- 
itiator codon ATG to base number 1158 (counted 
from ATG), but O’Brien’s data had one-base 
omissions, G, C and C at base numbers 1159, 1170 
and 1357, respectively. The first and second one- 
base omissions cause frame-shift variations in the 
predicted amino acid sequence of ASL and the 
third deletion causes the reading frame to return to 
the initial frame. We also found two base- 
substitutions which, however, cause no amino acid 
substitutions in the present reading frame (see 
fig.2). 
In order to confirm our nucleotide sequence, we 
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sequenced peptides (K-peptides) which had been 
derived from purified human liver ASL by diges- 
tion with lysylendopeptidase. We isolated 15 dif- 
ferent peptides, whose amino acid compositions 
were consistent with those of the peptides 
predicted from the cDNA sequence. We sequenced 
three of these peptides. 
These were assumed to be K-10, K-19 whose 
nucleotide sequence involves two bases omitted in 
O’Brien’s sequence, and K-21, the C-terminal pep- 
tide. The results revealed that the sequences of the 
middle portion of K-10, the whole of K-19 and the 
N-terminal 24 residues of K-21 are exactly as 
predicted (fig.2). It therefore seems that the amino 
acid sequence deduced by our nucleotide analysis is 
almost entirely correct (we have no information 
about the N-terminal amino acid) and that 
O’Brien’s nucleotide sequence had two one-base 
omissions at the position shown in the present 
study. We were unable to find direct evidence for 
the third omission, but as Amaya et al. [7] pointed 
out, rat and human ASL amino acid sequences 
become homologous again just after the one-base 
omission we posit, strongly supporting the 
presence of a third one-base omission in O’Brien’s 
sequence. As the results show, the predicted amino 
acid sequence of human ASL in the present study 
is highly homologous with the rat sequence along 
the entire sequence (9OVo identical). 
Wistow and Piatigorsky [12] reported that 6 
crystallin, the major protein of the embryonic lens 
in birds and reptiles, belongs to the same protein 
superfamily as ASL. They showed that chicken 61 
and 62 crystallins are, respectively, 58 and 62% 
identical to the predicted amino acid sequence 
published by O’Brien et al. [l]. They further 
postulated a frame shift in the human ASL se- 
quence by an insertion of G after base 1272 and an 
insertion of C after 1281 of O’Brien’s cDNA se- 
quence (these correspond to bases 1159 and 1170 in 
the present sequence), deletions of G at positions 
1457 and 1461 (bases 1345 and 1349 in the present 
sequence), and gaps in the amino acid sequence. 
These postulations yield predicted protein se- 
quences that are 64 and 69% identical to chicken 
61 and 62 crystallins, respectively. As we show in 
fig.2, the one-base insertion at the two positions 
they postulated are at the correct positions. The 
amino acid sequence predicted from the present 
cDNA study is 68% identical to chicken 62 
Volume 234, number 2 FEBS LETTERS July 1988 
crystallin without any rearrangement of nucleotide 
and amino acid sequences. We are now analyzing 
ASL deficiency using the probes prepared from the 
cDNA clones isolated in the present study. 
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